Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Nasopharyngeal Carcinoma 18Squamous Cell Carcinoma of Head and Neck 11Head and Neck Neoplasms 9Recurrence 2Nasopharyngeal Neoplasms 2Pathologic Complete Response 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Diseases 1Hypopharyngeal Neoplasms 1Carcinoma 1

Interventions

pembrolizumab 35Cetuximab 18Gemcitabine 14Nivolumab 13Cisplatin 13Paclitaxel 10Carboplatin 9Cyclophosphamide 7cemiplimab 6Fluorouracil 6Specimen Handling 5Magnetic Resonance Spectroscopy 5Docetaxel 5fludarabine 4durvalumab 4aldesleukin 4Immune Checkpoint Inhibitors 4Biopsy 4fludarabine phosphate 3Valproic Acid 3Radiation 3Interleukin-2 3Drug Therapy 3Bevacizumab 3130-nm albumin-bound paclitaxel 3tislelizumab 2sintilimab 2avelumab 2apatinib 2Tablets 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × nimotuzumab × Head & Neck × Clear all
NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Sun Yat-sen University

Phase 2 Recruiting
208 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡